Here's Why Moderna (MRNA) Fell More Than Broader Market

Moderna (MRNA) shares fell 2.45% in recent trading, underperforming the S&P 500, though the stock gained 15.65% over the past month. Upcoming financial results are expected to show an EPS of -$2.97, a 10.81% improvement year-over-year, but revenue is projected to decline by 45.64% to $131 million; full-year revenue is estimated at $2.08 billion, a 35.72% decrease from the prior year.

Analysis

Moderna (MRNA) recently experienced a daily share price decline of 2.45% to $26.68, underperforming the S&P 500's 1.13% loss. This short-term pullback contrasts with its significant 15.65% gain over the past month, which surpassed both the Medical sector's 3.07% rise and the S&P 500's 3.55% advance. Investor focus is now on Moderna's upcoming financial release, where earnings per share (EPS) are projected at -$2.97, representing a 10.81% improvement (a smaller loss) compared to the same quarter last year. However, this is set against a sharply contrasting revenue forecast of $131 million, a substantial 45.64% decrease year-over-year. For the full fiscal year, consensus estimates anticipate an EPS of -$9.78, a 10.26% deterioration from the prior year, and revenue of $2.08 billion, down 35.72%. Despite these challenging top-line and full-year earnings projections, the Zacks Consensus EPS estimate has seen a positive revision, moving 1.28% higher over the past month, indicating some increased analyst optimism for near-term profit potential. Currently, Moderna holds a Zacks Rank of #3 (Hold), and its industry, Medical - Biomedical and Genetics, ranks in the top 32% of over 250 industries.

Key Decisions for Investors

• Investors should closely monitor Moderna's upcoming earnings release, particularly the substantial projected revenue decline and management's outlook, given the mixed signals.
• The recent 15.65% monthly stock gain juxtaposed with anticipated weak quarterly revenue and a deteriorating full-year EPS outlook suggests potential for increased volatility around the earnings announcement.
• Given the Zacks #3 (Hold) rating, positive near-term EPS estimate revisions, but significant revenue contraction forecasts, a cautious approach is warranted, assessing if the current valuation balances these conflicting factors.